Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe revision tag on the page was updated from v3.6.0 to v3.6.3, signaling a newer site build; no visible content changes to the study details are expected.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now includes a recruitment status update 'No longer looking for participants' and adds new help/navigation links (How to Read a Study Record, Common Questions, How to Join a Study). A Revision: v3.6.0 notice was added, and the Intervention/Treatment heading formatting was adjusted while the older Revision: v3.5.5 note was removed.SummaryDifference0.3%

- Check27 days agoChange DetectedThe page displays a new revision label, updating from v3.5.4 to v3.5.5 to reflect a minor update to the study record.SummaryDifference0.0%

- Check49 days agoChange DetectedRevision tag updated to v3.5.4, replacing the previous v3.5.3, indicating an updated set of study documents on the page. This reflects a documentation revision rather than a change to the study data or eligibility criteria.SummaryDifference0.0%

- Check63 days agoChange DetectedTaoyuan, Taiwan has been added as a site and Taoyuan District, Taiwan has been removed from the study locations. This updates the geographic footprint of the trial sites for INSIGHT.SummaryDifference0.0%

- Check70 days agoChange DetectedThe page’s footer “Revision” has been updated from v3.5.2 to v3.5.3, indicating a platform/version change rather than a change to the trial’s published information.SummaryDifference0.0%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.